Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Websites |
     
  3. Global Business Websites |
     
  4. Sitemap |
  5. Help
  1. Font size

    Reduce font size Increase font size  
 
 

Contact

Sanofi

Sanofi House
44 on Grand Central Office Park
2 Bond Street
Grand Central Extension 1
Midrand 16

Tel: +27 (0)11 256 3700
Fax: +27 (0)11 847 5099

If your question is related to an emergency, please consult your doctor or emergency unit.

Medical Information and Pharmacovigilance


Content :

Oncology

Cancer Being a Research driven company we are committed to develop new and innovative products to provide more effective cancer therapies through the development of novel therapies to address the unmet medical need of our patients.

 

Our History

Cancer has high a global disease burden with 12,662,600 new cases reported globally each year.  The picture is no different in South Africa with 74,700 new cases reported each year. It is estimated that 153,000 patients are currently living with cancer. The most common cancer types in South Africa include Breast, Prostate, Oesophagus, Lung, Cervix and Colorectal cancer.

Sanofi has a long legacy in oncology and has been a key stakeholder in the oncology fraternity since 1980 through its legacy companies; Noristan, Hoechst Marion Roussel, Rhone Poulenc Rohrer, Aventis and Sanofi -Synthelabo. Sanofi currently markets 12 products with indications in the most prevalent solid tumour types; Breast, Colorectal cancer, Prostate, Lung, Gastic and Head & Neck as well as some haematological malignancies. Through these products patients could benefit from extended survival or improved quality of life.

 

Being a Research driven company we are committed to develop new and innovative products to provide more effective cancer therapies through the development of novel therapies to address the unmet medical need of our patients. Numerous products are currently in late stage development for both solid tumours and haematological malignancies.

The acquisition of Genzyme by Sanofi in 2011 increased the Sanofi Oncology footprint in the field of haematological malignancies as well as solid organ and bone marrow transplantation.
Sanofi strives to provide a diversified oncology offering through its generic arm, Zentiva and some strategic partnerships to deliver a cost effective oncology solution in a cost sensitive healthcare environment to all South Africans.

Sanofi is a founding member of numerous foundations like the Breast Health Foundation and the Prostate Cancer Foundation that are involved in the areas of disease awareness and support. Through the work with these organisations Sanofi strives to promote awareness leading to early diagnosis of these diseases which will have a significant improvement in the outcome for patients diagnosed with cancer.

Sanofi is committed to remain a key partner in the field of oncology in keeping with its strong oncology heritage through a diversified offering of novel medicine and quality generics in both the field of oncology and transplantation.

 

Updated June 20, 2013

Module :